Ra Pharmaceuticals — Corporate Update (December 2017)
29 slides from Ra Pharmaceuticals's corporate update, Dec 8, 2017
Slide 1: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy, regulatory and clinical progress and therapeutic potential of our p
Slide 2: Executive Summary
Executive Summary Positive Interim Phase 2 Data Provides Foundation for C5 Inhibitor Franchise Lead clinical program: RA101495 SC Potent, synthetic, macrocyclic peptide inhibitor of complement C5 Convenient, self-administered, subcutaneous (SC) dosing Phase 2 program in paroxysmal nocturnal hemoglob
Slide 3: Phase 2 PNH Program Design
Phase 2 PNH Program Design Goal: Dose-finding study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of RA101495 SC in patients with PNH Design: Open-label (12 weeks) with long-term extension Global Program addressing 3 PNH populations Eculizumab Naï
Slide 4: Global Phase 2 PNH Program
Global Phase 2 PNH Program Rapid enrollment at major PNH referral centers across multiple geographies Finland United States Canada United Kingdom Germany New Zealand Hungary Australia Denmark 5 18 sites in 9 countries (29 patients enrolled) Contributions from all geographies Strong investigator supp
Slide 5: Global Phase 2 PNH Program
Global Phase 2 PNH Program ' (a) Pharma Rapid enrollment at major PNH referral centers across multiple geographies de — ee a United Kingdom, Germany Finland — sa = ies" i * Denmark Hungary Australia New Zealand > 18 sites in 9 countries (29 patients enrolled) > Contributions from all geographies > S
Slide 6: Naïve Cohort – Complete Baseline Characteristics
Eculizumab Naïve Cohort – Complete Baseline Characteristics Study population is consistent with real-world eculizumab naïve population 7 Parameter Patients (n=10) Age in years, median (range) 56 (32, 81) Females, n (%) 6 (60) Disease duration in years, median (range) 0.8 (0.01, 12) LDH (U/L), mean,
Slide 7: Naïve Cohort – Complete Primary Endpoint Met
Eculizumab Naïve Cohort – Complete Primary Endpoint Met Rapid, near complete, and sustained inhibition of complement activity observed in sRBC assay 1 5 0 0 1 0 0 1 0 0 0 5 0 5 0 0 1 . 5 x U L N 1 0 0 0 B a s e l i n e 1 0 1 2 3 4 6 8 1 0 1 2 1 6 2 0 2 4 2 3 4 6 8 1 0 1 2 1 6 2 0 2 4 R A 1 0 1 4 9 5
Slide 8: Naïve Cohort – Complete Overlay: RA101495 SC and Eculizumab Phase 3 Data
Eculizumab Naïve Cohort – Complete Overlay*: RA101495 SC (Naïve) and Eculizumab Phase 3 Data1,2 ** RA101495 N= 10 10 10 10 10 10 10 7 5 3 1Hillmen et al. N Engl J Med 2006 2U.S. FDA/CDER. (2007) BLA 125166 Pharmacometrics Review Eculizumab/Soliris *Not a head-to-head comparison. No head-to-head comp
Slide 9: Naïve Cohort – Complete Notable Case Studies
Eculizumab Naïve Cohort – Complete Notable Case Studies Maximum activity was observed in the patient with the highest baseline LDH No recurrence of breakthrough hemolysis observed at week 6 in association with viral infection 2 5 0 0 2 5 0 0 2 0 0 0 2 0 0 0 1 5 0 0 1 5 0 0 1 0 0 0 1 0 0 0 5 0 0 5 0
Slide 10: Naïve Cohort – Complete Improvements in Transfusion Dependence
Eculizumab Naïve Cohort – Complete Improvements in Transfusion Dependence Observed after Week 0 visit* 50% of treatment naïve, transfusion-dependent patients have been transfusion-free on RA101495 SC *All patients have completed a minimum of 12 weeks dosing 11 Subject ID Transfused during 6 months p
Slide 11: Naïve Cohort – Complete QOL and Treatment Satisfaction
Eculizumab Naïve Cohort – Complete QOL and Treatment Satisfaction QOL Assessment Mean FACIT Fatigue Scores (SE), n=10 Treatment Satisfaction Score Mean (SE), n=10 5 Very Satisfied 4 Satisfied Neutral 3 Dissatisfied 2 Very Dissatisfied 1 Increase of 5.9 points from baseline to Week 12 QOL = quality o
Slide 12: Eculizumab Naive Cohort – Complete QOL and Treatment Satisfaction
TT a a a RS TT Te Te ee ee Eculizumab Naive Cohort — Complete QOL and Treatment Satisfaction Re) Pharma QOL Assessment Treatment Satisfaction Score Mean FACIT Fatigue Scores (SE), n=10 Mean (SE), n=10 ws0 Very Satisfied 5 = 35.2 Sy Satisfied 4 = Neutral 3 x Disatted 2 ary Week weeks Weekit Very Diss
Slide 13: Switch Cohort – Ongoing Switch Population: Response to Long-Term Eculizumab Therapy
Eculizumab Switch Cohort – Ongoing Switch Population: Response to Long-Term Eculizumab Therapy Two distinct populations after 3 years of eculizumab treatment 80% 20% Hillmen et al. Br J Hematol 2013 14
Slide 14: Switch Cohort – Ongoing Baseline Characteristics
Eculizumab Switch Cohort – Ongoing Baseline Characteristics Study population is overrepresented by poor responders to eculizumab who remain transfusion-dependent on long-term therapy (69% in study vs 20% real-world1) 1Hillmen et al. Br J Hematol 2013 15 Parameter Patients (n=16) Age in years, median
Slide 15: Switch Cohort – Ongoing Near Complete Complement Inhibition Observed
Eculizumab Switch Cohort – Ongoing Near Complete Complement Inhibition Observed Near complete, sustained, and uninterrupted inhibition of complement activity has been observed in sRBC assay during and after eculizumab washout, which exceeded the level of inhibition present at eculizumab trough (Week
Slide 16: Switch Cohort – Ongoing Robust LDH Control in Transfusion-Independent Patients
Eculizumab Switch Cohort – Ongoing Robust LDH Control in Transfusion-Independent Patients - In transfusion-independent eculizumab patients (~80% of real-world population on long-term treatment), switching to RA101495 SC has resulted in stable LDH levels and no episodes of breakthrough hemolysis In t
Slide 17: Switch Cohort – Ongoing Case Study: Successful Switching from Eculizumab
Eculizumab Switch Cohort – Ongoing Case Study: Successful Switching from Eculizumab to RA101495 SC Example of successful switching from eculizumab to RA101495 SC with no LDH excursions Last dose of eculizumab was two weeks prior to baseline visit 1 5 0 0 1 0 0 0 5 0 0 1 . 5 x U L N 0 B a s e l i n e
Slide 18: Inadequate Responder Cohort
Eculizumab Inadequate Responder Cohort 19
Slide 19: Inadequate Responder Cohort – Ongoing Case Study: First Inadequate Responder
Inadequate Responder Cohort – Ongoing Case Study: First Inadequate Responder (USA) - 53 yr. old M Caucasian with elevated LDH and documented intolerance to eculizumab (fatigue and pain post-infusions) receiving 450mg every 2 weeks Since switching to RA101495 SC, LDH has been well-controlled and pain
Slide 20: RA101495 SC Phase 2 PNH Program Safety and Tolerability
RA101495 SC Phase 2 PNH Program Safety and Tolerability Cumulative RA101495 SC exposure: Over 300 patient-weeks No dosing interruptions, down-titrations, or discontinuations due to tolerability No meningococcal infections observed No thromboembolic events observed ~100% compliance with once daily su
Slide 21: RA101495 SC Phase 2 PNH Program Summary
RA101495 SC Phase 2 PNH Program Summary Primary endpoint met in naïve cohort (p=0.002) In treatment-naïve patients, LDH reductions, transfusion avoidance, and QOL improvements are similar to observations from published eculizumab Phase 3 data Successful switching observed for transfusion-independent
Slide 22: RA101495 SC Potential 1st Line Therapy in PNH
RA101495 SC Potential 1st Line Therapy in PNH Product profile and pricing flexibility provide potential to establish RA101495 SC as 1st line therapy in PNH Designed to expand patient access through convenient, self-administered therapy Leveraging key properties of RA101495 SC to develop an optimal c
Slide 23: Opportunity to Expand Patient Access with a More Convenient and Cost-Effective C5 Inhibitor
Opportunity to Expand Patient Access with a More Convenient and Cost Naïve patients: “PNH: Majority of patients with PNH have yet to initiate treatment” (Alexion 3Q17 Earnings Presentation, Oct. 26, 2017) PNH Registry data (2017 ASH Abstracts) Effective C5 Inhibitor ~16,000 PNH patients WW Transfusi
Slide 24: Alternative Pathway and Complement Cascade: C5 Inhibition
ARltAer1n0at1iv4e9P5atShCway Classical Pathway Lectin Pathway InAhcitibvaitteidobny noonf-sCelof cmellsplemeAncttivaAtecdtbiyvaitntyiboindy-Panhtiagesneco2mpPlerxoesvidesActivated by pathogen su Read-ThrCo3ugh Across Multiple C1q -–MC1er d– iCa1ts ed Diseases Factor D, Factor B C2, C3, C4 C5-Mediate
Slide 25: RA101495 SC Large Market Opportunity Across Multiple C5 Indications
RA101495 SC Large Market Opportunity Across Multiple C5 Indications Undertreated, segmented populations, rare vs. ultra rare pricing, and convenience offer the opportunity to capture and expand multiple market segments across initial target indications Worldwide population Treated population (est.)
Slide 26: Executive Summary
Executive Summary Positive Interim Phase 2 Data Provides Foundation for C5 Inhibitor Franchise Lead clinical program: RA101495 SC Potent, synthetic, macrocyclic peptide inhibitor of complement C5 Convenient, self-administered, subcutaneous (SC) dosing Phase 2 program in paroxysmal nocturnal hemoglob
Slide 27: Executive Summary
Executive Summary Positive Interim Phase 2 Data Provides Foundation for C5 Inhii itor Franchise > Lead clinical program: RA101495 SC Potent, synthetic, macrocyclic peptide inhibitor of complement C5 Convenient, self-administered, subcutaneous (SC) dosing Phase 2 program in paroxysmal nocturnal hemog
Slide 28: Contact: Jen Robinson
Contact: Jen Robinson Senior Director, Investor Relations & Corporate Communications jrobinson@rapharma.com
Slide 29: Contact: Jen Robinson
Ra/ Pharma Contact: Jen Robinson Senior Director, Investor Relations & Corporate Communications jrobinson@rapharma.com
Ra Pharmaceuticals — Corporate Update (December 2017) on 6ix